Tuberous Sclerosis

Is regulatory red tape costing Africa its pharma future? Dr. Stavros Nicolaou argues that prolonged regulatory reviews and flawed procurement keep African manufacturers sidelined—despite proven capacity—fueling import dependence, trade deficits, and missed jobs. He outlines a pragmatic three-point plan (priority reviews/parallel WHO submissions, better subsidies, and continental pooled procurement) to jump-start local production and attract investment. 🔍 Read the full article to see the evidence and policy actions needed to turn imports into sustainable, locally made medicines. #SyenzaNews #pharmaceuticals #regulatoryaffairs #healthcarepolicy #MarketAccess

🌍 Did you know the global burden of tuberculosis (TB) among children has dropped significantly over the past three decades? Our recent analysis reveals a remarkable 37.4% reduction in TB incidence and a staggering 71.7% decrease in deaths from 1990 to 2021. Yet, challenges persist, especially in low SDI regions where this public health threat continues to expose disparities in healthcare access and outcomes. Look into the full article to explore these critical insights and the implications for future strategies in TB management. #SyenzaNews #globalhealth #HealthcareInnovation

The escalating prevalence of chronic diseases coupled with an ageing population is leading to a significant surge in demand for continuous home and institutional care. With professional resources in Québec becoming increasingly limited, virtual care tools have emerged as a crucial solution to ensure access to care and services. The COVID-19 pandemic has accelerated the use of virtual care tools, promoting continuity of care when in-person visits became risky or impossible. These tools, ranging from telemonitoring to teleconsultation, are becoming […]

Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by […]